Jon Lim, FRCP PhD
@drjonlim.bsky.social
Senior Lecturer & Consultant Medical Oncologist in Advanced #Immunotherapy + #CellTherapy at @manchester.ac.uk & The Christie • RISE Lead & MANIFEST Deputy Lead • ESMO #TranslationalResearch Faculty
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
🚀 Kicking off the new year with our next #ChristieFellowship session!
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
January 15, 2026 at 9:12 PM
🚀 Kicking off the new year with our next #ChristieFellowship session!
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
🤔 Do patients with cancer and clinicians see disease status the same way?
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
January 13, 2026 at 5:46 PM
🤔 Do patients with cancer and clinicians see disease status the same way?
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social.
🔗 www.stem.org.uk/resources/li...
🔗 www.stem.org.uk/resources/li...
January 4, 2026 at 10:25 PM
The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social.
🔗 www.stem.org.uk/resources/li...
🔗 www.stem.org.uk/resources/li...
7/11
This suggested that DNGR-1–dependent cross-presentation preferentially reveals cytoskeletal neoantigens, placing immune pressure on tumours to lose them ⚖️.
We tested this directly 🔬.
Some predicted F-actin–binding protein neoantigens were:
✔️ able to bind MHC I
✔️ genuinely immunogenic 𝘪𝘯 𝘷𝘪𝘷𝘰
This suggested that DNGR-1–dependent cross-presentation preferentially reveals cytoskeletal neoantigens, placing immune pressure on tumours to lose them ⚖️.
We tested this directly 🔬.
Some predicted F-actin–binding protein neoantigens were:
✔️ able to bind MHC I
✔️ genuinely immunogenic 𝘪𝘯 𝘷𝘪𝘷𝘰
January 2, 2026 at 4:57 PM
7/11
This suggested that DNGR-1–dependent cross-presentation preferentially reveals cytoskeletal neoantigens, placing immune pressure on tumours to lose them ⚖️.
We tested this directly 🔬.
Some predicted F-actin–binding protein neoantigens were:
✔️ able to bind MHC I
✔️ genuinely immunogenic 𝘪𝘯 𝘷𝘪𝘷𝘰
This suggested that DNGR-1–dependent cross-presentation preferentially reveals cytoskeletal neoantigens, placing immune pressure on tumours to lose them ⚖️.
We tested this directly 🔬.
Some predicted F-actin–binding protein neoantigens were:
✔️ able to bind MHC I
✔️ genuinely immunogenic 𝘪𝘯 𝘷𝘪𝘷𝘰
6/11
That’s when things clicked 💡.
Tumours from DNGR-1–deficient mice were enriched for mutations in 𝗙-𝗮𝗰𝘁𝗶𝗻–𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀 – which decorate F-actin, the ligand recognised by DNGR-1.
Not microtubules ❌
Not random proteins ❌
That’s when things clicked 💡.
Tumours from DNGR-1–deficient mice were enriched for mutations in 𝗙-𝗮𝗰𝘁𝗶𝗻–𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀 – which decorate F-actin, the ligand recognised by DNGR-1.
Not microtubules ❌
Not random proteins ❌
January 2, 2026 at 4:57 PM
6/11
That’s when things clicked 💡.
Tumours from DNGR-1–deficient mice were enriched for mutations in 𝗙-𝗮𝗰𝘁𝗶𝗻–𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀 – which decorate F-actin, the ligand recognised by DNGR-1.
Not microtubules ❌
Not random proteins ❌
That’s when things clicked 💡.
Tumours from DNGR-1–deficient mice were enriched for mutations in 𝗙-𝗮𝗰𝘁𝗶𝗻–𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀 – which decorate F-actin, the ligand recognised by DNGR-1.
Not microtubules ❌
Not random proteins ❌
3/11
To address this, we turned to chemical carcinogenesis models 🐭, and subsequently generated >100 primary tumour cell lines 🧫.
Tumours arising in DNGR-1–deficient mice behaved much like those from immunodeficient hosts i.e. often rejected when transplanted into immunocompetent mice.
To address this, we turned to chemical carcinogenesis models 🐭, and subsequently generated >100 primary tumour cell lines 🧫.
Tumours arising in DNGR-1–deficient mice behaved much like those from immunodeficient hosts i.e. often rejected when transplanted into immunocompetent mice.
January 2, 2026 at 4:57 PM
3/11
To address this, we turned to chemical carcinogenesis models 🐭, and subsequently generated >100 primary tumour cell lines 🧫.
Tumours arising in DNGR-1–deficient mice behaved much like those from immunodeficient hosts i.e. often rejected when transplanted into immunocompetent mice.
To address this, we turned to chemical carcinogenesis models 🐭, and subsequently generated >100 primary tumour cell lines 🧫.
Tumours arising in DNGR-1–deficient mice behaved much like those from immunodeficient hosts i.e. often rejected when transplanted into immunocompetent mice.
My main PhD paper is finally out! 🎉
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
January 2, 2026 at 4:57 PM
My main PhD paper is finally out! 🎉
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
✨ #ESMOImmuno25
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
December 10, 2025 at 4:58 PM
✨ #ESMOImmuno25
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
December 9, 2025 at 1:54 PM
Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
🚀 Save the Date!
We’re excited to launch our flagship TIL Summit in Manchester: "Unlocking TIL Therapy: A New Era for Melanoma Care in the UK"
🗓 11 March 2026
📍 The Midland Hotel, Manchester
We’re excited to launch our flagship TIL Summit in Manchester: "Unlocking TIL Therapy: A New Era for Melanoma Care in the UK"
🗓 11 March 2026
📍 The Midland Hotel, Manchester
November 29, 2025 at 11:05 AM
🚀 Save the Date!
We’re excited to launch our flagship TIL Summit in Manchester: "Unlocking TIL Therapy: A New Era for Melanoma Care in the UK"
🗓 11 March 2026
📍 The Midland Hotel, Manchester
We’re excited to launch our flagship TIL Summit in Manchester: "Unlocking TIL Therapy: A New Era for Melanoma Care in the UK"
🗓 11 March 2026
📍 The Midland Hotel, Manchester
🚨 Save the Date!
Next #ChristieFellows session:
“Preparing a Grant Proposal for PhD or Research Projects”
🎤 Dr Jamie Weaver
🗓️ Tue 18 Nov 2025 | 12:30–13:30
📍 Seminar 4&5, Edu Centre
Learn how to pitch your idea & navigate the grant process from an early-career clinical academic.
#TeamManchester 🐝
Next #ChristieFellows session:
“Preparing a Grant Proposal for PhD or Research Projects”
🎤 Dr Jamie Weaver
🗓️ Tue 18 Nov 2025 | 12:30–13:30
📍 Seminar 4&5, Edu Centre
Learn how to pitch your idea & navigate the grant process from an early-career clinical academic.
#TeamManchester 🐝
November 12, 2025 at 4:55 PM
🚨 Save the Date!
Next #ChristieFellows session:
“Preparing a Grant Proposal for PhD or Research Projects”
🎤 Dr Jamie Weaver
🗓️ Tue 18 Nov 2025 | 12:30–13:30
📍 Seminar 4&5, Edu Centre
Learn how to pitch your idea & navigate the grant process from an early-career clinical academic.
#TeamManchester 🐝
Next #ChristieFellows session:
“Preparing a Grant Proposal for PhD or Research Projects”
🎤 Dr Jamie Weaver
🗓️ Tue 18 Nov 2025 | 12:30–13:30
📍 Seminar 4&5, Edu Centre
Learn how to pitch your idea & navigate the grant process from an early-career clinical academic.
#TeamManchester 🐝
Delighted to be part of the #ESMOAmbassadors team at #ESMO25! 🌍
Let’s connect and discuss the latest news here in Berlin >>> and beyond!
#ONEOncologyCommunity
@myesmo.bsky.social
Let’s connect and discuss the latest news here in Berlin >>> and beyond!
#ONEOncologyCommunity
@myesmo.bsky.social
October 19, 2025 at 10:20 AM
Delighted to be part of the #ESMOAmbassadors team at #ESMO25! 🌍
Let’s connect and discuss the latest news here in Berlin >>> and beyond!
#ONEOncologyCommunity
@myesmo.bsky.social
Let’s connect and discuss the latest news here in Berlin >>> and beyond!
#ONEOncologyCommunity
@myesmo.bsky.social
🌟 Tour de force proffered paper by Dr Charlotte Spencer, Histopathology SpR + recent PhD Fellow in @turajliclab.bsky.social @crick.ac.uk
Huge congrats on the ESMO Merit Award 🎉 So well deserved — proud of you, my friend! 💫
#ESMO25 #TranslationalResearch #TRACERxRenal
Huge congrats on the ESMO Merit Award 🎉 So well deserved — proud of you, my friend! 💫
#ESMO25 #TranslationalResearch #TRACERxRenal
October 18, 2025 at 8:49 AM
🌟 Tour de force proffered paper by Dr Charlotte Spencer, Histopathology SpR + recent PhD Fellow in @turajliclab.bsky.social @crick.ac.uk
Huge congrats on the ESMO Merit Award 🎉 So well deserved — proud of you, my friend! 💫
#ESMO25 #TranslationalResearch #TRACERxRenal
Huge congrats on the ESMO Merit Award 🎉 So well deserved — proud of you, my friend! 💫
#ESMO25 #TranslationalResearch #TRACERxRenal
💥 Is it prime time for adoptive cell therapy in solid tumours?
📚 Special Educational Session on the state-of-the-art and future of cell therapies - evolving fast from promise to practice.
👀 Watch this space…
#ESMO25 #ESMOAmbassadors #CellTherapy #Immunotherapy
📚 Special Educational Session on the state-of-the-art and future of cell therapies - evolving fast from promise to practice.
👀 Watch this space…
#ESMO25 #ESMOAmbassadors #CellTherapy #Immunotherapy
October 18, 2025 at 7:49 AM
💥 Is it prime time for adoptive cell therapy in solid tumours?
📚 Special Educational Session on the state-of-the-art and future of cell therapies - evolving fast from promise to practice.
👀 Watch this space…
#ESMO25 #ESMOAmbassadors #CellTherapy #Immunotherapy
📚 Special Educational Session on the state-of-the-art and future of cell therapies - evolving fast from promise to practice.
👀 Watch this space…
#ESMO25 #ESMOAmbassadors #CellTherapy #Immunotherapy
Strong representation from our Experimental Cancer Medicines Team (ECMT) at The Christie, led by Dr Matthew Krebs at #ESMO25.
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
October 17, 2025 at 3:24 PM
Strong representation from our Experimental Cancer Medicines Team (ECMT) at The Christie, led by Dr Matthew Krebs at #ESMO25.
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity.
#TeamManchester 🐝
@mcrcnews.bsky.social
Proud of my colleague Prof Fiona Thistlethwaite - Chair and Abstract Discussant at the Developmental Therapeutics track here at #ESMO25.
#AICTteam
#TeamManchester 🐝
@mcrcnews.bsky.social
#AICTteam
#TeamManchester 🐝
@mcrcnews.bsky.social
October 17, 2025 at 3:03 PM
Proud of my colleague Prof Fiona Thistlethwaite - Chair and Abstract Discussant at the Developmental Therapeutics track here at #ESMO25.
#AICTteam
#TeamManchester 🐝
@mcrcnews.bsky.social
#AICTteam
#TeamManchester 🐝
@mcrcnews.bsky.social
Exciting days ahead in Berlin 🇩🇪 for #ESMO25!
Some of our core team from @christieinstitute.bsky.social are here at the #ESMO25 Congress - come say hi 👋!
Special shout-out to our #YoungOncologists colleagues - Always keen to connect, and discuss opportunities in Manchester. @mcrcnews.bsky.social
Some of our core team from @christieinstitute.bsky.social are here at the #ESMO25 Congress - come say hi 👋!
Special shout-out to our #YoungOncologists colleagues - Always keen to connect, and discuss opportunities in Manchester. @mcrcnews.bsky.social
October 17, 2025 at 9:26 AM
Exciting days ahead in Berlin 🇩🇪 for #ESMO25!
Some of our core team from @christieinstitute.bsky.social are here at the #ESMO25 Congress - come say hi 👋!
Special shout-out to our #YoungOncologists colleagues - Always keen to connect, and discuss opportunities in Manchester. @mcrcnews.bsky.social
Some of our core team from @christieinstitute.bsky.social are here at the #ESMO25 Congress - come say hi 👋!
Special shout-out to our #YoungOncologists colleagues - Always keen to connect, and discuss opportunities in Manchester. @mcrcnews.bsky.social
🎓 Honoured to chair the PhD viva of Maitane Márquez López at @biogipuzkoa.bsky.social | @ehu.eus with Prof Iker Badiola 🇪🇸 and Prof Irina Estrela-Lopis 🇩🇪.
Congrats to Maitane, and her supervisors Prof Charles Lawrie and Prof Andreas Seifert, on a successful defence! All the best for the future.
Congrats to Maitane, and her supervisors Prof Charles Lawrie and Prof Andreas Seifert, on a successful defence! All the best for the future.
October 10, 2025 at 4:30 PM
🎓 Honoured to chair the PhD viva of Maitane Márquez López at @biogipuzkoa.bsky.social | @ehu.eus with Prof Iker Badiola 🇪🇸 and Prof Irina Estrela-Lopis 🇩🇪.
Congrats to Maitane, and her supervisors Prof Charles Lawrie and Prof Andreas Seifert, on a successful defence! All the best for the future.
Congrats to Maitane, and her supervisors Prof Charles Lawrie and Prof Andreas Seifert, on a successful defence! All the best for the future.
🎓 Fully-funded 4-yr MRC PhD @officialuom.bsky.social!
Join a world-class team exploring how the microenvironment drives CRS in CAR-T therapy.
🌍 Open globally | 💥 Translational science
🗓️ Apply by 8 Nov 2025
🔗 www.findaphd.com/phds/project...
#PhDOpportunity #TeamManchester 🐝
@uom-dcs.bsky.social
Join a world-class team exploring how the microenvironment drives CRS in CAR-T therapy.
🌍 Open globally | 💥 Translational science
🗓️ Apply by 8 Nov 2025
🔗 www.findaphd.com/phds/project...
#PhDOpportunity #TeamManchester 🐝
@uom-dcs.bsky.social
October 7, 2025 at 10:34 PM
🎓 Fully-funded 4-yr MRC PhD @officialuom.bsky.social!
Join a world-class team exploring how the microenvironment drives CRS in CAR-T therapy.
🌍 Open globally | 💥 Translational science
🗓️ Apply by 8 Nov 2025
🔗 www.findaphd.com/phds/project...
#PhDOpportunity #TeamManchester 🐝
@uom-dcs.bsky.social
Join a world-class team exploring how the microenvironment drives CRS in CAR-T therapy.
🌍 Open globally | 💥 Translational science
🗓️ Apply by 8 Nov 2025
🔗 www.findaphd.com/phds/project...
#PhDOpportunity #TeamManchester 🐝
@uom-dcs.bsky.social
Great discussion today at @cgtcatapult.bsky.social & CERSI-AT on how #AI and #machinelearning is reshaping the development + testing of #AdvancedTherapies.
Exciting times ahead for the field - collaboration between all stakeholders (NHS, academia, industry, regulators) is the key to success!
Exciting times ahead for the field - collaboration between all stakeholders (NHS, academia, industry, regulators) is the key to success!
October 3, 2025 at 12:42 AM
Great discussion today at @cgtcatapult.bsky.social & CERSI-AT on how #AI and #machinelearning is reshaping the development + testing of #AdvancedTherapies.
Exciting times ahead for the field - collaboration between all stakeholders (NHS, academia, industry, regulators) is the key to success!
Exciting times ahead for the field - collaboration between all stakeholders (NHS, academia, industry, regulators) is the key to success!
🎓 New academic year, new opportunities!
🚀 Launching a refreshed Fellows’ Programme at @christieinstitute.bsky.social - focused on career development, leadership & opportunities to help trainees grow as future leaders, researchers & educators.
All fellows & residents @mcrcnews.bsky.social welcome!
🚀 Launching a refreshed Fellows’ Programme at @christieinstitute.bsky.social - focused on career development, leadership & opportunities to help trainees grow as future leaders, researchers & educators.
All fellows & residents @mcrcnews.bsky.social welcome!
October 1, 2025 at 10:53 AM
🎓 New academic year, new opportunities!
🚀 Launching a refreshed Fellows’ Programme at @christieinstitute.bsky.social - focused on career development, leadership & opportunities to help trainees grow as future leaders, researchers & educators.
All fellows & residents @mcrcnews.bsky.social welcome!
🚀 Launching a refreshed Fellows’ Programme at @christieinstitute.bsky.social - focused on career development, leadership & opportunities to help trainees grow as future leaders, researchers & educators.
All fellows & residents @mcrcnews.bsky.social welcome!
Back from an inspiring trip to Toronto 🇨🇦 for the 1st C8 Symposium, hosted by @pmresearch-uhn.bsky.social team.
Proud to represent #TeamManchester 🐝 & showcase our #immunotherapy + #celltherapy programmes, including #MANIFESTuk & soon-to-launch #RISE.
Global collaboration drives progress! 🌍✨
Proud to represent #TeamManchester 🐝 & showcase our #immunotherapy + #celltherapy programmes, including #MANIFESTuk & soon-to-launch #RISE.
Global collaboration drives progress! 🌍✨
September 29, 2025 at 6:38 AM
Back from an inspiring trip to Toronto 🇨🇦 for the 1st C8 Symposium, hosted by @pmresearch-uhn.bsky.social team.
Proud to represent #TeamManchester 🐝 & showcase our #immunotherapy + #celltherapy programmes, including #MANIFESTuk & soon-to-launch #RISE.
Global collaboration drives progress! 🌍✨
Proud to represent #TeamManchester 🐝 & showcase our #immunotherapy + #celltherapy programmes, including #MANIFESTuk & soon-to-launch #RISE.
Global collaboration drives progress! 🌍✨
🔹 Priorities – prospective clinical recruitment across NHS sites & expanding our partner network.
🔹 Looking ahead – focusing on sustainability, long-term impact & training.
Privileged to represent such a committed team & grateful to hear feedback/ideas as we continue to shape MANIFEST together 🚀.
🔹 Looking ahead – focusing on sustainability, long-term impact & training.
Privileged to represent such a committed team & grateful to hear feedback/ideas as we continue to shape MANIFEST together 🚀.
September 3, 2025 at 9:23 PM
🔹 Priorities – prospective clinical recruitment across NHS sites & expanding our partner network.
🔹 Looking ahead – focusing on sustainability, long-term impact & training.
Privileged to represent such a committed team & grateful to hear feedback/ideas as we continue to shape MANIFEST together 🚀.
🔹 Looking ahead – focusing on sustainability, long-term impact & training.
Privileged to represent such a committed team & grateful to hear feedback/ideas as we continue to shape MANIFEST together 🚀.
From vision to momentum: MANIFEST at 12 months 💡➡️📈
Honoured to share our progress at the UK Cancer Research Strategy Forum held in London today, chaired by Prof Peter Johnson, as part of the Office for Life Sciences Cancer Mission.
On behalf of
@turajliclab.bsky.social
@manifest-cirrp.bsky.social
Honoured to share our progress at the UK Cancer Research Strategy Forum held in London today, chaired by Prof Peter Johnson, as part of the Office for Life Sciences Cancer Mission.
On behalf of
@turajliclab.bsky.social
@manifest-cirrp.bsky.social
September 3, 2025 at 9:23 PM
From vision to momentum: MANIFEST at 12 months 💡➡️📈
Honoured to share our progress at the UK Cancer Research Strategy Forum held in London today, chaired by Prof Peter Johnson, as part of the Office for Life Sciences Cancer Mission.
On behalf of
@turajliclab.bsky.social
@manifest-cirrp.bsky.social
Honoured to share our progress at the UK Cancer Research Strategy Forum held in London today, chaired by Prof Peter Johnson, as part of the Office for Life Sciences Cancer Mission.
On behalf of
@turajliclab.bsky.social
@manifest-cirrp.bsky.social
🚀 Applications now open for the 2026 Tessa Jowell Neuro-oncology Fellowship!
A prestigious 12-month funded post at The Christie to develop world-class clinical, research & leadership skills in brain tumour care, working with experts.
Deadline: 5th Sep 2025
📥 For further information/to apply 👇
A prestigious 12-month funded post at The Christie to develop world-class clinical, research & leadership skills in brain tumour care, working with experts.
Deadline: 5th Sep 2025
📥 For further information/to apply 👇
August 14, 2025 at 1:01 PM
🚀 Applications now open for the 2026 Tessa Jowell Neuro-oncology Fellowship!
A prestigious 12-month funded post at The Christie to develop world-class clinical, research & leadership skills in brain tumour care, working with experts.
Deadline: 5th Sep 2025
📥 For further information/to apply 👇
A prestigious 12-month funded post at The Christie to develop world-class clinical, research & leadership skills in brain tumour care, working with experts.
Deadline: 5th Sep 2025
📥 For further information/to apply 👇